Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.

Human Diseases; Drug resistance: antineoplastic
BRITE hierarchy

Pteropus alecto (black flying fox) [GN:pale]

PMID:14576837

Siddik ZH

Cisplatin: mode of cytotoxic action and molecular basis of resistance.

Oncogene 22:7265-79 (2003)
DOI:10.1038/sj.onc.1206933

PMID:26184483

Martinez-Balibrea E, Martinez-Cardus A, Gines A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Buges C, Bystrup S, Esteller M, Abad A

Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.

Mol Cancer Ther 14:1767-76 (2015)
DOI:10.1158/1535-7163.MCT-14-0636

PMID:17625587

Kelland L

The resurgence of platinum-based cancer chemotherapy.

Nat Rev Cancer 7:573-84 (2007)
DOI:10.1038/nrc2167

PMID:26886018

Dilruba S, Kalayda GV

Platinum-based drugs: past, present and future.

Cancer Chemother Pharmacol 77:1103-24 (2016)
DOI:10.1007/s00280-016-2976-z

PMID:23442359

Lu HP, Chao CC

Cancer cells acquire resistance to anticancer drugs: an update.

Biomed J 35:464-72 (2012)
DOI:10.4103/2319-4170.104411

PMID:24074238

Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S

Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.

Expert Rev Mol Med 15:e12 (2013)
DOI:10.1017/erm.2013.13

PMID:21892204

Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G

Molecular mechanisms of cisplatin resistance.

Oncogene 31:1869-83 (2012)
DOI:10.1038/onc.2011.384

PMID:17336087

Stewart DJ

Mechanisms of resistance to cisplatin and carboplatin.

Crit Rev Oncol Hematol 63:12-31 (2007)
DOI:10.1016/j.critrevonc.2007.02.001

PMID:20647037

Koberle B, Tomicic MT, Usanova S, Kaina B

Cisplatin resistance: preclinical findings and clinical implications.

Biochim Biophys Acta 1806:172-82 (2010)
DOI:10.1016/j.bbcan.2010.07.004

PMID:25546083

Jacobsen C, Honecker F

Cisplatin resistance in germ cell tumours: models and mechanisms.

Andrology 3:111-21 (2015)
DOI:10.1111/andr.299

PMID:14609433

Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK

Chemoresistance in human ovarian cancer: the role of apoptotic regulators.

Reprod Biol Endocrinol 1:66 (2003)
DOI:10.1186/1477-7827-1-66

Sousa GF, Wlodarczyk SR, Monteiro G.

Carboplatin: molecular mechanisms of action associated with chemoresistance.

Braz J Pharm Sci 50:693-701 (2014)
DOI:10.1590/S1984-82502014000400004

PMID:24874729

Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G

Systems biology of cisplatin resistance: past, present and future.

Cell Death Dis 5:e1257 (2014)
DOI:10.1038/cddis.2013.428

PMID:25058905

Dasari S, Tchounwou PB

Cisplatin in cancer therapy: molecular mechanisms of action.

Eur J Pharmacol 740:364-78 (2014)
DOI:10.1016/j.ejphar.2014.07.025

PMID:20811617

Basu A, Krishnamurthy S

Cellular responses to Cisplatin-induced DNA damage.

J Nucleic Acids 2010:201367 (2010)
DOI:10.4061/2010/201367

PMID:19190080

Chaudhry P, Asselin E

Resistance to chemotherapy and hormone therapy in endometrial cancer.

Endocr Relat Cancer 16:363-80 (2009)
DOI:10.1677/ERC-08-0266

PMID:26867799

Li X, Lin Z, Zhang B, Guo L, Liu S, Li H, Zhang J, Ye Q

beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.

Sci Rep 6:21010 (2016)
DOI:10.1038/srep21010

PMID:15607932

Safaei R, Howell SB

Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.

Crit Rev Oncol Hematol 53:13-23 (2005)
DOI:10.1016/j.critrevonc.2004.09.007